76240-27-2

Usage

Uses

Used in Adhesives and Sealants Industry:
7-Hydroxycoumarin is used as a photosensitizer in adhesives and sealants for its ability to absorb light, enhancing the curing process and improving the performance of these materials.
Used in Coatings Industry:
In the coatings industry, 7-Hydroxycoumarin is utilized as a photosensitizer to improve the curing and drying process of coatings, leading to better adhesion and durability.
Used in Organic Dyes:
7-Hydroxycoumarin is used as a component in the creation of organic dyes due to its fluorescent properties, which emit a blue glow when exposed to ultraviolet light. This makes it suitable for applications requiring specific color characteristics and visual effects.
Used in Light-Sensitive Materials:
This chemical compound is employed in the development of light-sensitive materials, where its ability to absorb light plays a crucial role in the functionality and performance of these materials.
Used in Pharmaceutical Research:
Although more research is needed, 7-Hydroxycoumarin is being studied for its potential pharmacological properties, such as antioxidant and antibacterial activities. If proven safe and effective, it could be used in the development of new drugs and treatments.
Used in Antioxidant Applications:
Some studies suggest that 7-Hydroxycoumarin may possess antioxidant properties, which could be utilized in various applications to protect against oxidative stress and related health issues.
Used in Antibacterial Applications:
The potential antibacterial properties of 7-Hydroxycoumarin are being investigated, and if confirmed, it could be used in the development of new antimicrobial agents to combat bacterial infections.

InChI:InChI=1/C9H8O3/c10-6-1-2-7-8(11)3-4-12-9(7)5-6/h1-2,5,10H,3-4H2

Upstream product

• 59887-89-7 7-hydroxy-4H-chromen-4-one 
• 42327-52-6 7-methoxy-chroman-4-one 
• 76240-23-8 3-(3-Hydroxyphenoxy)propanenitrile 
• 79566-30-6 7-benzyloxy-1-benzopyran-4-one 
• 29682-12-0 1-[4-(benzyloxy)-2-hydroxyphenyl]ethanone 
• 108-46-3 recorcinol 
• 7623-09-8 2-chloropropionyl chloride 
• 445408-54-8 7-acetoxy-chroman-4-one 
• 107-94-8 chloropropionic acid 
• 625-36-5 2-chloropropionyl chloride 
• 90721-47-4 3-(3-hydroxyphenoxy)propanoic acid 
• 49855-03-0 3-(3-methoxyphenoxy)propionic acid 
• 150-19-6 O-methylresorcine 
• 151884-07-0 2',4'-dihydroxy-3-chloropropiophenone 

Downstream Products

• 31042-20-3 7-(benzyloxy)chroman-4-one 
• 83162-84-9 Bonducellin 
• 111254-31-0 (E)-3-(4-hydroxy-3-methoxybenzylidene)-7-hydroxychroman-4-one 
• 104778-14-5 Sappanone A 
• 57052-72-9 2,3-Dihydro-7-hydroxy-4H-1-benzopyran 
• 116512-96-0 (3E)-2,3-dihydro-7-hydroxy-3-[(3-hydroxy-4-methoxyphenyl)-methylene]-4H-1-benzopyran-4-one 
• 610778-85-3 (Z)-7-hydroxy-3-(4'-methoxybenzylidene)chroman-4-one 
• 118975-25-0 7-acetoxy-2,3-dihydro-3-(4-methoxybenzylidene)-1-benzopyran-4-one 
• 853760-23-3 7-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}-2,3-dihydro-4H-chromen-4-one 
• 110064-50-1 3'-deoxy-sappanone A 
• 793724-32-0 (E)-7-hydroxy-3-(2',4'-dimethoxybenzylidene)chroman-4-one 
• 911376-43-7 methyl 4-[(trans-4-tert-butylcyclohexyl)amino]chromane-7-carboxylate 
• 929010-44-6 4-[1-(4-tert-butyl-cyclohexyl)-3-(4-trifluoromethoxy-phenyl)-ureido]-chroman-7-carboxylic acid methyl ester 

Relevant academic research and scientific papers

The evaluation of 1-tetralone and 4-chromanone derivatives as inhibitors of monoamine oxidase

Abstract: Monoamine oxidase (MAO) is of much clinical relevance, and inhibitors of this enzyme are used in the treatment for neuropsychiatric and neurodegenerative disorders such as depression and Parkinson’s disease. The present study synthesises and evaluates the MAO inhibition properties of a series of 33 1-tetralone and 4-chromanone derivatives in an attempt to discover high-potency compounds and to expand on the structure–activity relationships of MAO inhibition by these classes. Among these series, eight submicromolar MAO-A inhibitors and 28 submicromolar MAO-B inhibitors are reported, with all compounds acting as specific inhibitors of the MAO-B isoform. The most potent inhibitor was a 1-tetralone derivative (1h) with IC50 values of 0.036 and 0.0011?μM for MAO-A and MAO-B, respectively. Interestingly, with the reduction of 1-tetralones to the corresponding alcohols, a decrease in MAO inhibition potency is observed. Among these 1-tetralol derivatives, 1p (IC50 = 0.785?μM) and 1o (IC50 = 0.0075?μM) were identified as particularly potent inhibitors of MAO-A and MAO-B, respectively. Potent compounds such as those reported here may act as leads for the future development of MAO-B specific inhibitors. Graphic abstract: The present study describes the MAO inhibitory activities of a series of 1-tetralone and 4-chromanone derivatives. Numerous high-potency MAO-B specific inhibitors were identified.[Figure not available: see fulltext.].

Asymmetric Transfer Hydrogenation of Arylidene-Substituted Chromanones and Tetralones Catalyzed by Noyori-Ikariya Ru(II) Complexes: One-Pot Reduction of C═C and C═O bonds

3-Arylidenechroman-4-ones and 2-arylidene-1-tetralones are hydrogenated to cis-benzylic alcohols in dr's and er's up to 99:1 via a C═C and C═O one-pot reduction in the presence of 2-5 mol % Noyori-Ikariya-type RuII chiral complexes and HCO2Na as a hydroge

INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR

Chromanone compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the inhibition of antigen presentation by HLA-DR.

Discovery of novel 2H-chromene-3-carbonyl derivatives as selective estrogen receptor degraders (SERDs): Design, synthesis and biological evaluation

Selective estrogen receptor degraders (SERDs) not only block ERα activity but degrade this receptor at the same time and are effective in relapsed ERα positive breast cancer patients who have accepted other endocrine therapies. Herein, through scaffold hopping of coumarin skeleton, a series of 2H-chromene-3-carbonyl-based SERDs with phenyl acrylic acid group as the side chain were designed and synthesized. Compound XH04 containing 7-hydroxy-2H-chromene-3-carbonyl skeleton exhibited the most potent activities in 2D (IC50 = 0.8 μM) and 3D cells culture models (MCF-7) and had the best ERα binding affinity as well. Furthermore, the significant antiestrogen property of compound XH04 was confirmed by inhibiting the expression of progesterone receptor (PgR) mRNA in MCF-7 cells. On the other hand, the outgoing ERα degradation property of compound XH04 was qualitatively and quantificationally verified by immunofluorescence analysis and Western blot assay in MCF-7 cells. Besides, compound XH04 repressed the expression level of Ki67 in MCF-7 cells and induced the apoptosis increase of this tumor cells in a dose-dependent manner like approved-SERD fulvestrant (2), while compound XH04 exhibited better preliminary pharmacokinetics in human and rat liver microsomes in vitro and a lower LogD7.4 value than fulvestrant. And further molecular docking study revealed that compound XH04 possessed a proverbial and typical binding model with ERα like other reported SERD. All these results confirmed that 7-hydroxy-2H-chromene-3-carbonyl structure could be a feasible skeleton for design of ERα antagonists including SERDs and compound XH04 is a promising candidate for further development of ERα + breast cancer therapy agents.

3-carbonyl-2H-benzopyran compounds or pharmaceutically acceptable salts thereof, preparation method and application of 3-carbonyl-2H-benzopyran compounds or pharmaceutically acceptable salts thereof

The invention discloses a 3-carbonyl-2H-benzopyran compound or a pharmaceutically acceptable salt thereof, a preparation method and application. The structural formula is shown in the specification. The compound plays a role of SERDs molecules, and is used for preparing medicines for treating or preventing various medical indications related to postmenopausal syndromes and treating ER (+) breast cancer.

Visible light mediated selective oxidation of alcohols and oxidative dehydrogenation of N-heterocycles using scalable and reusable La-doped NiWO4nanoparticles

Visible light-mediated selective and efficient oxidation of various primary/secondary benzyl alcohols to aldehydes/ketones and oxidative dehydrogenation (ODH) of partially saturated heterocycles using a scalable and reusable heterogeneous photoredox catalyst in aqueous medium are described. A systematic study led to a selective synthesis of aldehydes under an argon atmosphere while the ODH of partially saturated heterocycles under an oxygen atmosphere resulted in very good to excellent yields. The methodology is atom economical and exhibits excellent tolerance towards various functional groups, and broad substrate scope. Furthermore, a one-pot procedure was developed for the sequential oxidation of benzyl alcohols and heteroaryl carbinols followed by the Pictet-Spengler cyclization and then aromatization to obtain the β-carbolines in high isolated yields. This methodology was found to be suitable for scale up and reusability. To the best of our knowledge, this is the first report on the oxidation of structurally diverse aryl carbinols and ODH of partially saturated N-heterocycles using a recyclable and heterogeneous photoredox catalyst under environmentally friendly conditions.

Vanadium-Catalyzed Oxidative Intramolecular Coupling of Tethered Phenols: Formation of Phenol-Dienone Products

A mild and efficient method for the vanadium-catalyzed intramolecular coupling of tethered free phenols is described. The corresponding phenol-dienone products are prepared directly in good yields with low catalyst loadings. Electronically diverse tethered phenol precursors are well tolerated, and the catalytic method was effectively applied as the key step in syntheses of three natural products and a synthetically useful morphinan alkaloid precursor.

Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease

A series of rasagiline-clorgyline hybrids was designed, synthesized and investigated in vitro for their inhibition of monoamine oxidase and amyloid-β aggregation. Most of compounds were found to be selective and highly potent hMAO-B inhibitors showing IC50 values in the nanomolar, and exhibited a moderate inhibition of amyloid-β aggregation. 7-((5-(methyl(prop-2-yn-1-yl)amino) pentyl)oxy)chroman-4-one (6j) was the most interesting compound identified in this research, endowed with higher hMAO-B potency (IC50 = 4 nM) and selectivity (SI > 25000) compared to the reference selective inhibitor rasagiline (IC50 = 141 nM, SI > 355), and exhibited good inhibitory activity against Aβ1-42 aggregation (40.78percent, 25 μM). Kinetic and molecular modeling studies revealed that 6j was a competitive reversible inhibitor for hMAO-B. Moreover, compound 6j displayed low toxicity and good neuroprotective effects in SH-SY5Y cell assay, and could penetrate the blood-brain barrier according to the parallel artificial membrane permeability assay. Pharmacokinetics assay revealed that compound 6j possessed good pharmacokinetic profiles after intravenous and oral administrations. Overall, these results highlighted that compound 6j was an effective and promising multitarget agent against Alzheimer's disease.

Chroman derivatives having estrogen receptor degradation activity and uses thereof

The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions.

ALPHA, BETA-UNSATURATED AMIDE COMPOUND

An object of the present invention is to provide an α,β-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like. The α,β-unsaturated amide compound represented by the following formula (I) or a pharmaceutically acceptable salt or the like thereof has anticancer activity and the like: [wherein, "A" represents optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents -O-, -S-, -SO2-, -NRX1- (wherein, RX1 represents hydrogen atom or lower alkyl), -CHRX2- (wherein, RX2 represents hydrogen atom or hydroxy), -CH=CH-, -CO- or -NH-CO-, and n1 and n2 are the same or different, and each represents 0 or 1].